Online inquiry

IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4216MR)

This product GTTS-WQ4216MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets Factor IX substitute gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000133.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2158
UniProt ID P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4216MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1863MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGEN1884
GTTS-WQ11438MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ7853MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ15949MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ2428MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 145
GTTS-WQ10718MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ40MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ7640MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GEN1029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW